Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

76.13USD
22 Feb 2019
Change (% chg)

$0.99 (+1.32%)
Prev Close
$75.14
Open
$75.50
Day's High
$76.44
Day's Low
$75.40
Volume
1,271,425
Avg. Vol
1,983,647
52-wk High
$76.44
52-wk Low
$56.81

Chart for

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

Financials

  ABT.N Industry Sector
P/E (TTM): 84.45 32.21 33.70
EPS (TTM): 0.65 -- --
ROI: 2.24 13.74 14.45
ROE: 4.07 16.49 15.96

Abbott misses revenue estimates, sees lackluster first-quarter profit

Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

23 Jan 2019

UPDATE 3-Abbott misses revenue estimates, sees lackluster first-qtr profit

Jan 23 Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

23 Jan 2019

Abbott Labs says M&A not a high priority now

Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.

23 Jan 2019

Abbott Labs says M&A not a high priority now

Jan 23 Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.

23 Jan 2019

Abbott Lab's fourth-quarter revenue rises 2.3 pct

Jan 23 Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices.

23 Jan 2019

Abbott, AbbVie settle TriCor marketing case for $25 million

Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

26 Oct 2018

UPDATE 2-Abbott, AbbVie settle TriCor marketing case for $25 mln

Oct 26 Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

26 Oct 2018

Abbott, AbbVie settle U.S. case over TriCor marketing for $25 mln

Oct 26 Abbott Laboratories and AbbVie Inc will pay $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for them prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

26 Oct 2018

Abbott Labs quarterly profit falls on higher tax expense

Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.

17 Oct 2018

UPDATE 1-Abbott Labs quarterly profit falls on higher tax expense

Oct 17 Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.

17 Oct 2018

Earnings vs. Estimates